47 completed, 20 recruiting, 12 active not recruiting, 9 unknown. 43 Phase 2, 25 Phase 1, 18 Not applicable, 3 Phase 3.
Follow Penile Neoplasms: new trials by email Literature Review of Penile Neoplasms trials Research Report on Penile Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb) - Penile Cancer | Phase 2 | Recruiting | Fudan University | 20 | 2026-09-01 | 2026-09-18 |
| Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile Cancer Pucotenlimab plus Becotatug Vedotin - Penile Cancer, Penile Squamous Cell Carcinoma (PSCC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-08-15 | 2026-08-17 |
| EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer Becotatug Vedotin, Pucotenlimab - Penile Cancer | Phase 2 | Recruiting | Jiyan Liu | 60 | 2026-07-22 | 2026-07-29 |
| QL1706 Plus Lenvatinib in Previously Treated Penile Cancer QL1706 + Lenvatinib - Penile Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 47 | 2026-04-10 | 2026-05-08 |
| DEfeating PEnile CAncer-2 open inguinal lymphadenectomy, robot-assisted inguinal lymphadenectomy - Penile Cancer, Penile Neoplasms Malignant | Not applicable | Recruiting | University Hospital Tuebingen | 80 | 2026-04-10 | 2026-09-30 |
| MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma MRG003, HX008 - Penile Cancer | Phase 1 | Recruiting | Jiyan Liu | 10 | 2026-02-12 | 2026-04-07 |
| A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER Cemiplimab - Penile Cancer | Phase 2 | Not yet recruiting | Hospital Israelita Albert Einstein | 42 | 2025-12-01 | 2025-08-03 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-06 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors Albumin-paclitaxel Injection - Paget Disease, Extramammary, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 100 | 2024-11-30 | 2024-12-20 |
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Enhanced Assistance During Radiotherapy for Unmet Essential Needs Standard assistance, Enhanced assistance - Bone Cancer, Brain Cancer | Not applicable | Completed | Washington University School of Medicine | 33 | 2024-10-04 | 2025-08-26 |
| Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | SCG Cell Therapy Pte. Ltd. | 66 | 2024-10-01 | 2024-07-17 |
| Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Carboplatin/Paclitaxel, Pembrolizumab, Partial or total penectomy with inguinal and/or pelvic lymph node dissection - Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Recruiting | The Netherlands Cancer Institute | 27 | 2024-08-13 | 2025-12-08 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Genital Wart, Penile Cancer | Phase 3 | Active not recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 9000 | 2024-07-11 | 2024-12-12 |
| Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma Glans-sparing surgery - Penile Cancer, Recurrent | Unknown | Universitaire Ziekenhuizen KU Leuven | 800 | 2024-06-03 | 2024-08-23 | |
| TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer Paclitaxel + Ifosfamide + Cisplatin & Toripalimab - Penile Cancer | Phase 2 | Completed | Sun Yat-sen University | 25 | 2024-05-31 | 2026-10-13 |
| FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer Administration of CC-3 - Colorectal Cancer, Breast Carcinoma | Phase 1 | Recruiting | German Cancer Research Center | 89 | 2024-01-12 | 2025-05-21 |
Showing 20 of 98. Sign in to see all of them.
Anus Neoplasms (40) · Uterine Cervical Neoplasms (37) · Vulvar Neoplasms (31) · Vaginal Neoplasms (24) · Urinary Bladder Neoplasms (22) · Prostatic Neoplasms (21) · Breast Neoplasms (16) · Carcinoma, Renal Cell (16) · Testicular Neoplasms (16) · Esophageal Neoplasms (14) · Neoplasms (14) · Oropharyngeal Neoplasms (14) · Head and Neck Neoplasms (13) · Melanoma (13)
Genital Diseases (98) · Genital Diseases, Male (98) · Genital Neoplasms, Male (98) · Neoplasms by Site (98) · Penile Diseases (98) · Urogenital Diseases (98) · Male Urogenital Diseases (97) · Urogenital Neoplasms (93) · Neoplasms (84) · Female Urogenital Diseases (57) · Female Urogenital Diseases and Pregnancy Complications (57) · Digestive System Diseases (45) · Digestive System Neoplasms (45) · Gastrointestinal Diseases (43) · Gastrointestinal Neoplasms (43)
Cisplatin (6) · Cyclophosphamide (5) · Nivolumab (5) · fludarabine (5) · pembrolizumab (5) · Ifosfamide (4) · Magnetic Resonance Spectroscopy (4) · Paclitaxel (4) · aldesleukin (4) · Ipilimumab (3) · Radiotherapy (3) · Adoptive Transfer (2) · Biopsy (2) · CTLA-4 Antigen (2) · Specimen Handling (2)
National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (5) · Sun Yat-sen University (4) · The Netherlands Cancer Institute (4) · Fudan University (3) · UNICANCER (3) · Christian Hinrichs (2) · HRYZ Biotech Co. (2) · Institute of Cancer Research, United Kingdom (2) · Jiyan Liu (2) · Regeneron Pharmaceuticals (2) · Shanghai Bovax Biotechnology Co., Ltd. (2) · The Affiliated Hospital of Qingdao University (2) · Travera Inc (2) · University of Maryland, College Park (2)
United States (45) · China (15) · Netherlands (7) · United Kingdom (7) · France (6) · Canada (4) · Germany (4) · Italy (4) · Belgium (3) · Brazil (3) · Sweden (3) · Puerto Rico (2) · Finland (1) · Hungary (1) · Ireland (1)
Andrea B Apolo (2) · Christian S Hinrichs, MD (2) · Hongxia Wang, Doctor (2) · Jian Zhang, Doctor (2) · William P. Tew, MD (2) · Xiaoli Nan (2) · Amit Bahl (1) · Andrea B Apolo, M.D. (1) · Andrea Necchi, MD (1) · Annika Bergman, PhD (1) · Antti S Rannikko, MD, PhD (1) · Asif Muneer, MD (1) · Aung Naing (1) · Baris Karakullukcu, MD, PhD (1)
PMID 19949018, PMID 22002018, PMID 35031545, PMID 18417462, PMID 19690306, PMID 20068553, PMID 20625118, PMID 22480131, PMID 25823737, PMID 27020837, PMID 27160946, PMID 29048177, PMID 29149611, PMID 30125350, PMID 30658128, PMID 30714987, PMID 31533818, PMID 32188704, PMID 32303619, PMID 32534809, PMID 32620211, PMID 32804590, PMID 32915679, PMID 33216356, PMID 33323462, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33770291, PMID 34108183, PMID 34241781, PMID 34613617, PMID 34671131, PMID 34725215, PMID 35618285, PMID 35999229, PMID 37487169, PMID 37568622, PMID 38558767, PMID 38600541, PMID 38954785, PMID 40212844, PMID 40588522, PMID 40881578, PMID 40965911, PMID 41143139, PMID 41163621, PMID 41468684, PMID 42094867, PMID 42342409
2014 (3), 2018 (2), 2019 (2), UM1CA186717 (2), 2015 (1), 2016 (1), P30CA023108 (1), P30CA069533 (1), R01CA101704 (1), R01CA219060 (1), U01CA121947 (1), U01CA287904 (1), U10CA032102 (1), U10CA180821 (1), UM1CA186712 (1)